
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis is supported by a compelling TYK2-focused pipeline, with envudeucitinib showing competitive clinical efficacy in psoriasis and a 54% PASI100 response rate at wk48, the highest reported among oral PsO programs, while NDA submission remains on track for 4Q26. The company’s thesis is further strengthened by the validation of TYK2 in PsO and SLE, plus the optionality from A-005, a CNS-penetrant candidate that could extend the platform into neuroinflammatory and neurodegenerative diseases. Despite commercial questions around twice-daily dosing, the profile still suggests meaningful upside versus Sotyktu and supports a favorable long-term outlook ahead of key catalysts in 2H26, 4Q26, 1H27, and 2027.
Bears say
Alumis is facing a deteriorating fundamental setup because envudeucitinib, despite strong psoriasis efficacy signals, must compete against once-daily incumbents and may enter the U.S. after Icotyde and zasocitinib, limiting commercial differentiation. The SLE program is a larger concern since the 408-patient Phase 2b LUMUS trial missed its primary and secondary endpoints in the overall population, leaving regulatory and pivotal-study requirements unclear and potentially delaying approval by 3-4 years if more trials are needed. Financially, cash fell to $431.3M from $502.3M, the company added a going-concern qualification, and management expects to raise capital before launch, creating dilution risk while 3Q26 net loss remained $94.9M.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Alumis Inc (ALMS) Forecast
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares